Dyne Therapeutics, INC. (DYN) — 10-Q Filings

10-Q Filings (6)

• Dyne's Q3 Loss Widens on Soaring R&D, Bolsters Cash with Offerings — Nov 5, 2025 Risk: high
  Dyne Therapeutics, Inc. reported a net loss of $108.041 million for the three months ended September 30, 2025, an increase from $97.125 million in the same peri
• Dyne's Net Loss Widens to $145.8M Amid R&D Ramp-Up — Jul 28, 2025 Risk: high
  Dyne Therapeutics, Inc. reported no revenue for the six months ended June 30, 2025, consistent with its clinical-stage status. The company's net loss for the si
• Dyne Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Dyne Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results and provided updates on its business act
• Dyne Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Dyne Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results, including details on its cash and c
• Dyne Therapeutics Q2 2024 Update — Aug 12, 2024 Risk: medium
  Dyne Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial position, including marketable securities and
• Dyne Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 2, 2024 Risk: medium
  Dyne Therapeutics, Inc. (DYN) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. Dyne Therapeutics, Inc. reported financial results for the quarter en

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX